GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript - Thomson StreetEvents

GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript

GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript - Thomson StreetEvents
GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript
Published Nov 29, 2021
24 pages (17237 words) — Published Nov 29, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of GSK.L corporate analyst meeting

  
Brief Excerpt:

...Operator Good day, everyone, and welcome to the Meet GSK Management: Getting Ahead of HIV Conference, hosted by David Redfern, Chairman of ViiV Healthcare and Chief Strategy Officer for GSK. My name is Cathy, and I'm your event manager today. (Operator Instructions) I would like to advise all parties, this conference is being recorded for my training purposes. And now I'd like to hand over to David. Please go ahead, sir. David Simon Redfern ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
GlaxoSmithKline PLC
Ticker
GSK.L
Time
3:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Firstly, on the pipeline, clearly, you have much to work with as you show in Slide 24. But I just wondered if you believe you've got all the potential combinations that you would like to have dolutegravir in house or are there other aspects, mechanisms you would be interested in, in this HIV space that would mean you would consider external partnerships? And then just secondly, for clarification. You mentioned earlier, Deborah, the IP for Dovato expiring in '28 and '29 in the U.S. and Europe effectively. I wonder if you can just detail when in those years you expect the big IP to roll off, whether there is anything different here versus the (inaudible) you have with dolutegravir (inaudible)?

Table Of Contents

GlaxoSmithKline PLC and HALEON PLC Consumer Healthcare Capital Markets Day Transcript – 2022-02-28 – US$ 54.00 – Edited Transcript of GSK.L corporate analyst meeting</ 28-Feb-22 12:30pm GMT

GlaxoSmithKline PLC to Discuss About Investing in Healthcare Innovations: A Case Study of Multi-stakelholder Capitalism in Practice Call Transcript – 2022-02-10 – US$ 54.00 – Edited Transcript of GSK.L conference call or presentation 10-Feb-22 1:00pm GMT

GlaxoSmithKline PLC Q4 2021 Earnings Call Transcript – 2022-02-09 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 9-Feb-22 2:00pm GMT

GlaxoSmithKline PLC at JPMorgan Healthcare Conference (Virtual) Transcript – 2022-01-11 – US$ 54.00 – Edited Transcript of GSK.L presentation 11-Jan-22 12:30pm GMT

GlaxoSmithKline PLC at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript – 2022-01-06 – US$ 54.00 – Edited Transcript of GSK.L presentation 6-Jan-22 1:00pm GMT

GlaxoSmithKline PLC Investor Science Event: ASN Kidney Week Transcript – 2021-11-07 – US$ 54.00 – Edited Transcript of GSK.L corporate analyst meeting</ 7-Nov-21 5:00pm GMT

GlaxoSmithKline PLC Q3 2021 Earnings Call Transcript – 2021-10-27 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 27-Oct-21 1:00pm GMT

GlaxoSmithKline PLC at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript – 2021-10-06 – US$ 54.00 – Edited Transcript of GSK.L presentation 6-Oct-21 5:00pm GMT

GlaxoSmithKline PLC at Citi BioPharma Conference (Virtual) Transcript – 2021-09-09 – US$ 54.00 – Edited Transcript of GSK.L presentation 9-Sep-21 5:25pm GMT

GlaxoSmithKline PLC Q2 2021 Earnings Call Transcript – 2021-07-28 – US$ 54.00 – Edited Transcript of GSK.L earnings conference call or presentation 28-Jul-21 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript" Nov 29, 2021. Alacra Store. May 04, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/GlaxoSmithKline-PLC-Meet-GSK-Management-Getting-Ahead-of-HIV-T15046497>
  
APA:
Thomson StreetEvents. (2021). GlaxoSmithKline PLC Meet GSK Management: Getting Ahead of HIV Transcript Nov 29, 2021. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/GlaxoSmithKline-PLC-Meet-GSK-Management-Getting-Ahead-of-HIV-T15046497>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.